文献速递核素与放射性配体治疗

分化良好的神经内分泌肿瘤患者经肽受体放射性核素治疗疾病控制后,生长抑素类似物似乎没有明显获益

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-03

这项前瞻性随机单中心研究纳入115例分化良好神经内分泌肿瘤患者,经肽受体放射性核素治疗(PRRT)后疾病稳定或缓解者按2:1随机分为生长抑素类似物(SSA)组74例和仅最佳支持治疗对照组41例。SSA组中位无进展生存期4.7年,对照组6.4年,两组无进展生存期和总生存期均无显著差异。

要点

  • PRRT后疾病控制的神经内分泌肿瘤患者中,后续SSA治疗似乎未带来更好的无进展生存期或总生存期。
  • SSA组进展比例70%(52/74)高于对照组46%(19/41),p=0.01。
  • 两组死亡比例78%(58/74)对73%(30/41),p=0.52,无显著差异。

核心结论

  • 在PRRT后疾病控制的患者中,后续SSA治疗似乎与更好的无进展生存期或总生存期无关。
  • PRRT后进展时是否继续使用SSA,需要在前瞻性随机对照多中心研究且样本相对同质的情况下评估。

研究设计与样本

  • 前瞻性、随机、单中心研究,共115例患者按2:1随机分为SSA组74例和对照组41例。
  • 主要入组标准为不可切除、局部晚期或转移性、组织学确认的分化良好神经内分泌肿瘤,无类癌综合征症状或生化诊断,PRRT前未使用SSA或使用≤3个月,且PRRT后疾病稳定或部分缓解或完全缓解。
  • SSA组给予醋酸奥曲肽长效释放剂每4周一次;对照组仅接受最佳支持治疗。
  • 主要终点为无进展生存期,次要终点为总生存期。

主要发现

  • 自首次PRRT活性给药至死亡或最新观察的中位随访时间为6.6年(25th-75th百分位3.18-10.22年)。
  • 115例中71例(62%)进展,SSA组52/74(70%),对照组19/41(46%),p=0.01。
  • 115例中88例(76%)死亡,SSA组58/74(78%),对照组30/41(73%),p=0.52。
  • SSA组中位无进展生存期4.7年(95%CI 2.8-7.7),对照组6.4年(95%CI 4.1-未达到)。
  • 总体中位总生存期为6.6年,两组无进展生存期和总生存期均无显著差异(p=0.129,p=0.985)。

局限性

  • 原文结论指出PRRT后进展时是否继续使用SSA需要在前瞻性、随机、对照、多中心研究且样本相对同质的情况下评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Peptide receptor radionuclide therapy (PRRT) and somatostatin analogues (SSAs) are commonly combined as primary treatment for neuroendocrine neoplasms (NEN), and SSAs given as maintenance. We sought to evaluate whether sequential therapy with PRRT followed by SSAs has progression or survival benefits in patients with NEN after disease control by PRRT. METHODS: This prospective, randomised, single-centre study had as principal eligibility criteria: unresectable, locally advanced, or metastatic, histologically confirmed well-differentiated NEN; no symptoms/biochemical diagnosis of carcinoid syndrome; no SSAs or ≤ 3 months of SSAs before PRRT; and stable disease or partial or complete response after PRRT. Altogether, 115 patients were randomised 2:1 to an SSA group (n = 74) given octreotide acetate LAR every 4 weeks, or a control group (n = 41) receiving only best supportive care. Octreotide treatment was to stop upon intolerable toxicity or patient refusal, or, at physician/patient discretion, upon NEN progression. The primary endpoint was progression-free survival (PFS), the secondary endpoint, and overall survival (OS). RESULTS: Median (25th-75th percentile) follow-up from the first PRRT activity to death or latest observation was 6.6 (3.18-10.22) years. During that time, 71/115 patients (62%) progressed, 52/74 (70%) in the SSA group, and 19/41 (46%) in the control group (p = 0.01). Eighty-eight/115 patients (76%) died, 58/74 (78%) in the SSA group, and 30/41 (73%) in the control group (p = 0.52). Median (95% CI) PFS was 4.7 (2.8-7.7) years in the SSA group, and 6.4 (4.1-not reached) years in controls. Overall, median OS was 6.6 years. Neither PFS nor OS differed between groups (p = 0.129, p = 0.985, respectively). CONCLUSIONS: In patients with disease control after PRRT, subsequent SSA treatment appeared not to be associated with better PFS or OS. Whether to continue SSA administration upon progression after PRRT requires evaluation in a prospective, randomised, controlled multicentre study with a relatively homogeneous sample.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Syguła A, Ledwon A, Hasse-Lazar K, et al. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2022. PMID: 35503379. doi:10.1007/s00259-022-05792-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。